You are here

Share:

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Showing 1-9 of 9 results found

SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation

Researchers at the National Cancer Institute (NCI) developed a novel mouse for the detection of TGF-ß signaling. This mouse provides the opportunity to study TGF-ß signaling in vivo and may be a useful model for preclinical pharmacology studies. The NCI seeks licensees for the TGF-ß reporter mouse.
  • Research Tools

Methods of Determining Homeostatic Perturbations

The Eunice Kennedy Shriver National Institute of Child Health and Human Development seeks research co-development partners and/or licensees to further develop and commercialize its methods of noninvasively and directly determining the absolute homeostatic state, metabolic activity, function, and viability of isolated cells, or tissues (ex vivo or in vivo), such as the Central Nervous System (CNS). The method uses Nuclear Magnetic Resonance or Magnetic Resonance Imaging measurements of the rate at which endogenous water exchanges across cell membranes.
  • Diagnostics

Tamperless Tensor Elastography Imaging

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of tamperless tensor elastography imaging in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications.
  • Diagnostics

Polymeric Delivery Platform for Therapeutics

The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations for a polymeric drug delivery platform that targets scavenger receptor A1 (SR-A1), a receptor highly expressed in macrophages, monocytes, mast cells, dendritic cells (myeloid lineages), and endothelial cells. The platform delivers various immunomodulatory therapeutic cargo including small molecule drugs, therapeutic peptides, and vaccines, to the lymphatic system and myeloid/antigen presenting cell (APC) sub-populations.
  • Therapeutics